Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature

Abstract

<abstract> <p>Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects motor and cognition functions. The etiology of Parkinson's disease remains largely unknown, but genetic and environmental factors are believed to play a role. The neurotransmitter dopamine is implicated in regulating movement, motivation, memory, and other physiological processes. In individuals with Parkinson's disease, the loss of dopaminergic neurons leads to a reduction in dopamine levels, which causes motor impairment and may also contribute to the cognitive deficits observed in some patients. Therefore, it is important to understand the pathophysiology that leads to the loss of dopaminergic neurons, along with reliable biomarkers that may help distinguish PD from other conditions, monitor its progression, or indicate a positive response to a therapeutic intervention. Important advances in the treatment, etiology, and pathogenesis of Parkinson's disease have been made in the past 50 years. Therefore, this review tries to explain the different possible mechanisms behind the depletion of dopamine in PD patients such as alpha-synuclein abnormalities, mitochondrial dysfunction, and 3,4-dihydroxyphenylacetaldehyde (DOPAL) toxicity, along with the current therapies we have and the ones that are in development. The clinical aspect of Parkinson's disease such as the manifestation of both motor and non-motor symptoms, and the differential diagnosis with similar neurodegenerative disease are also discussed.</p> </abstract>

Cysteamine HCl Administration Impedes Motor and Olfactory Functions, Accompanied by a Reduced Number of Dopaminergic Neurons, in Experimental Mice: A Preclinical Mimetic Relevant to Parkinson’s Disease

“…The degeneration of dopamine-producing neurons in the SN and OB is a prominent neuropathogenic hallmark of PD [40,41]. As a consequence, reduced levels of dopamine in the brain have been directly linked to motor deficits, olfactory dysfunction, and memory loss in PD [42]. Interestingly, S. Szabo and C.H.…”

A Comprehensive Review of Secondary Movement Disorders

“…Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopamineproducing neurons in the substantia nigra, a region of the brain involved in movement control [110]. This loss of dopamine leads to the motor symptoms of Parkinson's disease, including bradykinesia (slowness of movement), rigidity, tremor, and postural instability.…”

The role of autophagy in Parkinson’s disease: a gender difference overview

“…Modulations in neurotransmitter distribution and receptor sensitivity may contribute to differences in PD motor symptoms between men and women. For example, dopamine is a neurotransmitter involved in the regulation of movement, and its deficiency is related to the motor symptoms of PD; changes in the function of dopaminergic receptors affect the transmission of nerve signals and the consequent manifestation of motor symptoms ( Ramesh and Arachchige, 2023 ). Many studies have reported that in women, motor symptoms tend to emerge later and are characterized by reduced rigidity, tremor, and a greater propensity to develop postural instability ( Cerri et al, 2019 ).…”